Q32 Bio (QTTB) – Research Analysts’ Recent Ratings Changes

Q32 Bio (NASDAQ: QTTB) has recently received a number of price target changes and ratings updates:

• 12/12/2024 – Q32 Bio had its price target lowered by analysts at BMO Capital Markets from $64.00 to $22.00. They now have an “outperform” rating on the stock.
• 12/11/2024 – Q32 Bio had its price target lowered by analysts at Piper Sandler from $85.00 to $20.00. They now have an “overweight” rating on the stock.
• 12/11/2024 – Q32 Bio had its price target lowered by analysts at Oppenheimer Holdings Inc. from $80.00 to $20.00. They now have an “outperform” rating on the stock.
• 12/11/2024 – Q32 Bio had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $22.00 price target on the stock, down previously from $90.00.
• 12/11/2024 – Q32 Bio was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.
• 12/11/2024 – Q32 Bio had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $9.00 price target on the stock, down previously from $68.00.
• 12/11/2024 – Q32 Bio was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 12/11/2024 – Q32 Bio had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $16.00 price target on the stock, down previously from $95.00.
• 12/6/2024 – Q32 Bio is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $64.00 price target on the stock.
• 10/24/2024 – Q32 Bio is now covered by analysts at Raymond James. They set a “strong-buy” rating and a $90.00 price target on the stock.

Q32 Bio Stock Up 7.5 %

NASDAQ QTTB traded up $0.25 during trading on Friday, reaching $3.59. The company’s stock had a trading volume of 843,423 shares, compared to its average volume of 119,175. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $43.73 million, a PE ratio of -0.25 and a beta of -0.46. Q32 Bio Inc. has a 1-year low of $3.02 and a 1-year high of $53.79. The business has a 50-day moving average price of $32.53 and a 200-day moving average price of $33.31.

Hedge Funds Weigh In On Q32 Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QTTB. Point72 Asset Management L.P. bought a new position in shares of Q32 Bio in the third quarter worth about $3,422,000. FMR LLC increased its position in Q32 Bio by 137.3% in the 3rd quarter. FMR LLC now owns 426,302 shares of the company’s stock worth $19,022,000 after buying an additional 246,664 shares during the period. Ensign Peak Advisors Inc increased its position in Q32 Bio by 150.6% in the 2nd quarter. Ensign Peak Advisors Inc now owns 64,481 shares of the company’s stock worth $1,157,000 after buying an additional 38,750 shares during the period. Harvard Management Co. Inc. acquired a new position in shares of Q32 Bio during the second quarter worth approximately $2,925,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Q32 Bio in the second quarter valued at approximately $315,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.